← Patient EducationTestosterone in menopausal women: what the research actually shows.
Testosterone is not just a "male" hormone — women produce it too, and levels fall with age. Here is the published evidence on benefits, risks and heart safety, in one page.
Reviewed by the Elevate Care Team · Dr. Eric W. Anderson, MD
The headline findings
The largest analysis of testosterone therapy in women found meaningful improvement in sexual desire, arousal and satisfaction in postmenopausal women — with no adverse signal on lipids, blood pressure or glucose at physiologic doses.Davis SR et al. The Lancet Diabetes & Endocrinology, 2019;7(10):754–766
Pooled analysis of five phase III trials of the 300 mcg/day testosterone patch: no significant changes in cholesterol, triglycerides, insulin, glucose or blood pressure, and no increase in heart attack, stroke or blood clots.Vitale C et al. Circulation, 2008;118:S_1137
The 2019 Global Consensus Position Statement — endorsed by the Endocrine Society, International Menopause Society, North American Menopause Society and others — concluded the one evidence-based use of testosterone in women is low sexual desire (HSDD) in postmenopausal women, at doses that restore normal premenopausal levels.Davis SR et al. J Clin Endocrinol Metab, 2019;104(10):4660–4666
How women differ from men
Women are treated at roughly 1/10th of a typical male dose — the goal is to restore the levels a healthy young woman makes naturally, not to exceed them.
In men, therapy targets low-T symptoms broadly. In women, the proven benefit is sexual desire and function; evidence for mood, cognition, bone and muscle is promising but not yet conclusive.
At physiologic doses, trials show no increase in cardiovascular events, and side effects are mostly mild and dose-related (acne, unwanted hair growth) — and reverse when dosing is adjusted.
There is no FDA-approved testosterone product for women in the U.S., so it is prescribed off-label — typically as a compounded cream or gel at female-appropriate dosing, with lab monitoring.
What we still don't know
Long-term heart data
Trials to date run 1–2 years. A dedicated long-term cardiovascular safety study in women has not been completed, which is why monitoring matters.
Beyond desire
Studies on energy, brain fog, bone density and muscle mass are underway, but the evidence isn't strong enough yet for the consensus to recommend treatment for those alone.
The Elevate approach
We test first. Your testosterone, estrogen and full metabolic panel are measured before any prescription, dosing is kept within normal female physiologic range, and every plan is reviewed by Dr. Eric W. Anderson, MD with follow-up labs to keep levels where they belong.